The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)
The FDA approved Troveldy to treat metastatic TNBC in people who have had at least two prior lines of treatment.
The National Comprehensive Cancer Network (NCCN) is a national panel of experts that creates guidelines for cancer treatment. NCCN recommends the following testing for targeted therapy in people with metastatic TNBC:
NCT03992131: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR). This is a study looking at the combination of the PARP inhibitor rucaparib in combination with other therapies, including Sacituzumab Govitecan in patients with an advanced/metastatic solid malignancy, including TNBC patients.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.